UBS’s Aoxing Pharmaceutical Company Inc. AXN Stock Holding History

UBS’s Portfolio AXN Stock Details AXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$56K	Buy	287,913 +287,244	+42,936%	+$91K	﹤0.01%	6693
2014 Q2	$0	Buy	+669	New	+$261	﹤0.01%	11091
2014 Q1	–	Sell	-861	Closed	–	–	11111
2013 Q4	$0	Buy	+861	New	+$227	﹤0.01%	11051
2013 Q3	–	Sell	-8,585	Closed	-$2K	–	10939
2013 Q2	$2K	Buy	+8,585	New	+$1.99K	﹤0.01%	9893

Other funds holding AXN

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

UBS's AXN Position: Q3 2014 in Review

UBS increased its Aoxing Pharmaceutical Company Inc. (AXN) stake by 42,936% in Q3 2014, buying an estimated $91K and bringing the position to 287,913 shares worth $56K. The position accounts for ﹤0.01% of the portfolio, ranked #6693.

UBS first reported a position in AXN in Q2 2013 and has held it in 4 quarters since. 4 funds tracked by Wall St. Rank hold AXN as of Q3 2014.

UBS held 287,913 shares of Aoxing Pharmaceutical Company Inc. worth $56K as of Q3 2014.
UBS bought 287,244 Aoxing Pharmaceutical Company Inc. shares in Q3 2014, an estimated $91K.
Aoxing Pharmaceutical Company Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #6693 holding.
UBS first reported a position in Aoxing Pharmaceutical Company Inc. in Q2 2013 and has held it in 4 quarters since.
4 funds tracked by Wall St. Rank held Aoxing Pharmaceutical Company Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.